Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?

Abstract The use of the adjuvant therapeutic antibody trastuzumab in breast cancer is associated with a range of cardiotoxic side effects despite successfully reducing the severity of outcomes cancer patients,. The most common cardiac effect, a reduction in left ventricular ejection fraction (LVEF),...

Full description

Bibliographic Details
Main Authors: Holden Eaton, Kerstin Nina Timm
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Cardio-Oncology
Subjects:
Online Access:https://doi.org/10.1186/s40959-023-00172-3
_version_ 1797836240669638656
author Holden Eaton
Kerstin Nina Timm
author_facet Holden Eaton
Kerstin Nina Timm
author_sort Holden Eaton
collection DOAJ
description Abstract The use of the adjuvant therapeutic antibody trastuzumab in breast cancer is associated with a range of cardiotoxic side effects despite successfully reducing the severity of outcomes cancer patients,. The most common cardiac effect, a reduction in left ventricular ejection fraction (LVEF), is a known precursor to heart failure and often requires interruption of chemotherapy to avoid endangering patients further. An understanding of trastuzumab’s cardiac-specific interactions is therefore critical in devising new methods to not only avoid permanent cardiac damage, but also prolong treatment time, and therefore effectiveness, for breast cancer patients. Increasingly, the use of exercise as a treatment has been indicated across the field of cardio-oncology due to encouraging evidence that it can protect against LVEF reductions and heart failure. This review explores the mechanisms of trastuzumab-mediated cardiotoxicity, as well as the physiological effects of exercise on the heart, in order to assess the suitability of exercise intervention for breast cancer patients on trastuzumab antibody-therapy. We furthermore draw comparison to existing evidence for exercise intervention as a cardioprotective treatment in doxorubicin-induced cardiotoxicity. Although preclinical evidence seems to support exercise-based approaches also in trastuzumab-cardiotoxicity, current clinical evidence is too limited to confidently recommend it as a treatment, largely owing to issues of adherence. Future studies should therefore examine how the variety and duration of exercise can be adjusted to improve treatment effectiveness at a more personalised level.
first_indexed 2024-04-09T15:06:45Z
format Article
id doaj.art-c2f534bd295e4e349935bbb0b70dc6db
institution Directory Open Access Journal
issn 2057-3804
language English
last_indexed 2024-04-09T15:06:45Z
publishDate 2023-04-01
publisher BMC
record_format Article
series Cardio-Oncology
spelling doaj.art-c2f534bd295e4e349935bbb0b70dc6db2023-04-30T11:29:54ZengBMCCardio-Oncology2057-38042023-04-019111010.1186/s40959-023-00172-3Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?Holden Eaton0Kerstin Nina Timm1Merton College, University of OxfordDepartment of Pharmacology, University of OxfordAbstract The use of the adjuvant therapeutic antibody trastuzumab in breast cancer is associated with a range of cardiotoxic side effects despite successfully reducing the severity of outcomes cancer patients,. The most common cardiac effect, a reduction in left ventricular ejection fraction (LVEF), is a known precursor to heart failure and often requires interruption of chemotherapy to avoid endangering patients further. An understanding of trastuzumab’s cardiac-specific interactions is therefore critical in devising new methods to not only avoid permanent cardiac damage, but also prolong treatment time, and therefore effectiveness, for breast cancer patients. Increasingly, the use of exercise as a treatment has been indicated across the field of cardio-oncology due to encouraging evidence that it can protect against LVEF reductions and heart failure. This review explores the mechanisms of trastuzumab-mediated cardiotoxicity, as well as the physiological effects of exercise on the heart, in order to assess the suitability of exercise intervention for breast cancer patients on trastuzumab antibody-therapy. We furthermore draw comparison to existing evidence for exercise intervention as a cardioprotective treatment in doxorubicin-induced cardiotoxicity. Although preclinical evidence seems to support exercise-based approaches also in trastuzumab-cardiotoxicity, current clinical evidence is too limited to confidently recommend it as a treatment, largely owing to issues of adherence. Future studies should therefore examine how the variety and duration of exercise can be adjusted to improve treatment effectiveness at a more personalised level.https://doi.org/10.1186/s40959-023-00172-3TrastuzumabCardiotoxicityExerciseMetabolismChemotherapyHeart failure
spellingShingle Holden Eaton
Kerstin Nina Timm
Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
Cardio-Oncology
Trastuzumab
Cardiotoxicity
Exercise
Metabolism
Chemotherapy
Heart failure
title Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
title_full Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
title_fullStr Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
title_full_unstemmed Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
title_short Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
title_sort mechanisms of trastuzumab induced cardiotoxicity is exercise a potential treatment
topic Trastuzumab
Cardiotoxicity
Exercise
Metabolism
Chemotherapy
Heart failure
url https://doi.org/10.1186/s40959-023-00172-3
work_keys_str_mv AT holdeneaton mechanismsoftrastuzumabinducedcardiotoxicityisexerciseapotentialtreatment
AT kerstinninatimm mechanismsoftrastuzumabinducedcardiotoxicityisexerciseapotentialtreatment